Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Dow
Merck
AstraZeneca
Moodys

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Litigation Details for DOW PHARMACEUTICAL SCIENCES, INC. v. TOLMAR, INC. (D.N.J. 2015)

See Plans and Pricing

« Back to Dashboard

DOW PHARMACEUTICAL SCIENCES, INC. v. TOLMAR, INC. (D.N.J. 2015)

Docket   Start Trial Date Filed 2015-11-09
Court District Court, D. New Jersey Date Terminated
Cause 35:271 Patent Infringement Assigned To Michael Andre Shipp
Jury Demand None Referred To Tonianne J. Bongiovanni
Parties DOW PHARMACEUTICAL SCIENCES, INC.; TOLMAR, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC
Patents 8,288,434; 8,663,699
Attorneys MELISSA ANNE CHUDEREWICZ
Firms Pepper Hamilton LLP
Link to Docket External link to docket
Small Molecule Drugs cited in DOW PHARMACEUTICAL SCIENCES, INC. v. TOLMAR, INC.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for DOW PHARMACEUTICAL SCIENCES, INC. v. TOLMAR, INC. (D.N.J. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-11-05 1 United States Patent Nos. 8,288,434 (“the ’434 patent”) and 8,663,699 (“the ’699 patent”) arising under….S. Patent and Trademark Office (“PTO”) issued the ’699 patent on March 4, 2014. The ’699 patent claims… THE PATENTS IN SUIT 8. The U.S. Patent and Trademark Office (“…(“PTO”) issued the ’434 patent on October 16, 2012. The ’434 patent claims, inter alia, formulations …. Dow is the assignee of the ’434 patent. A copy of the ’434 patent is attached hereto as Exhibit A. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Moodys
AstraZeneca
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.